Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of nivolumab with high dietary fiber intake in immunotherapy-resistant solid tumors (K-TAIL 203)
jRCTs031230606Phase 2Suspended
- Sponsor
- Taiyo Kagaku
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), esophageal cancer and gastric cancer (GC), sponsored by Taiyo Kagaku. Primary endpoint: Rate of progression-free survival at 6 months. Started Jan 2024; status: suspended.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)esophageal cancergastric cancer (GC)
Beyond the preview
Go deeper on jRCTs031230606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230606.